Notice type: 3rd Party Publications
Date: 23/07/2014
Important Safety Information communication from Clinigen Healthcare Ltd. on recommendations for use and important risks (nephrotoxicity, QTc prolongation, reproductive toxicity and off label use) associated with Vibativ (telavancin).
Important Safety Information - Vibativ (telavancin)